Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director · President and CEO | February 01, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date February 01, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2034-01-31 | Direct | 500,000 |
Reported balance
After 2024-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2019 Filed May 17, 2019 22:27 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 14,335 | $1.63 | $23,366.05 |
DisclosureSEC source: 0000899243-19-014037 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| April 18, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 4,616 | Not disclosed Strike: $1.63 | Not disclosed |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · derivative · entry 12 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,335 Underlying: Common Stock · 4,616 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F6 · price: Not applicable. F7 · derivative.exercise_date: The shares subject to this option became fully vested and exercisable on October 4, 2015. Read SEC document |
| April 18, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 6,843 | Not disclosed Strike: $1.63 | Not disclosed |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · derivative · entry 11 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,843 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F6 · price: Not applicable. F5 · derivative.exercise_date: The shares subject to this option became fully vested and exercisable on May 30, 2015. Read SEC document |
| April 18, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,616 | $16.02 | $73,925.24 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,881 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F4 · price: Represents the weighted average sale price of the shares sold ranging from $16.00 to $16.04 per share. The Reporting person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| April 18, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 4,616 | $1.63 | $7,524.08 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| April 18, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 6,843 | $16.01 | $109,583.80 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,881 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F4 · price: Represents the weighted average sale price of the shares sold ranging from $16.00 to $16.04 per share. The Reporting person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| April 18, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 6,843 | $1.63 | $11,154.09 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 7,449 | Not disclosed Strike: $1.63 | Not disclosed |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · derivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,951 Underlying: Common Stock · 7,449 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F6 · price: Not applicable. F7 · derivative.exercise_date: The shares subject to this option became fully vested and exercisable on October 4, 2015. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 1,092 | Not disclosed Strike: $1.63 | Not disclosed |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · derivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,843 Underlying: Common Stock · 1,092 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F6 · price: Not applicable. F5 · derivative.exercise_date: The shares subject to this option became fully vested and exercisable on May 30, 2015. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 7,449 | $16.18 | $120,544.19 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,881 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F3 · price: Represents the weighted average sale price of the shares sold ranging from $16.00 to $16.84 per share. The Reporting person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 7,449 | $1.63 | $12,141.87 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,092 | $16.11 | $17,587.97 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,881 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F2 · price: Represents the weighted average sale price of the shares sold ranging from $16.00 to $16.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 1,092 | $1.63 | $1,779.96 |
DisclosureSEC source: 0001209191-19-025373 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.63 | Not disclosed |
DisclosureSEC source: 0001209191-19-020986 · doc4.xml · derivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,935 Underlying: Common Stock · 20,000 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F4 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to this option became fully vested and exercisable on May 30, 2015. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 20,000 | $17.61 | $352,160.00 |
DisclosureSEC source: 0001209191-19-020986 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,881 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F2 · price: Represents the weighted average sale price of the shares sold ranging from $17.27 to $17.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 20,000 | $1.63 | $32,600.00 |
DisclosureSEC source: 0001209191-19-020986 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 500,000 | Not disclosed Strike: $16.55 | Not disclosed |
DisclosureSEC source: 0001209191-19-003023 · doc4.xml · derivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-01-06 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2019 such that this option is fully exercisable on January 1, 2023. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003023 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,881 F1 · security: Award of Restricted Stock Units that vests with respect to 1/2 of the underlying shares on January 7, 2021, and with respect to 1/4 of the underlying shares on each of January 7, 2022 and January 7, 2023. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 450,000 | Not disclosed Strike: $11.03 | Not disclosed |
DisclosureSEC source: 0001209191-18-043451 · doc4.xml · derivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2028-07-17 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 18, 2018 such that this option is fully exercisable on July 18, 2022. Read SEC document |
| July 18, 2018 Filed Aug 3, 2018 20:09 UTC Amendment | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 152,000 | Not disclosed Strike: $11.03 | Not disclosed |
DisclosureSEC source: 0001209191-18-045267 · doc4a.xml · derivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,000 Underlying: Common Stock · 152,000 shares Expires 2028-07-17 F1 · shares: The number of shares reported on this amended Form 4 reflects the correct number of shares underlying the stock option granted to Mr. Wolchko on July 18, 2018. F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 18, 2018 such that this option is fully exercisable on July 18, 2022. F1 · derivative.underlying_shares: The number of shares reported on this amended Form 4 reflects the correct number of shares underlying the stock option granted to Mr. Wolchko on July 18, 2018. F1 · balance_after: The number of shares reported on this amended Form 4 reflects the correct number of shares underlying the stock option granted to Mr. Wolchko on July 18, 2018. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 348,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001209191-18-003925 · doc4.xml · derivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,000 Underlying: Common Stock · 348,000 shares Expires 2028-01-15 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 800 | $4.07 | $3,256.00 |
DisclosureSEC source: 0001209191-17-057149 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,881 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 43,125 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $4.16 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes previously reported shares of Common Stock underlying RSUs granted to the reporting person, which are subject to certain vesting conditions. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 16,368 | $3.87 | $63,344.16 |
DisclosureSEC source: 0001209191-17-057149 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,681 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 43,125 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.53 to $4.08 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes previously reported shares of Common Stock underlying RSUs granted to the reporting person, which are subject to certain vesting conditions. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 250,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-17-002633 · doc4.xml · derivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.